BioAlliance Pharma Presents New Results on its AMEP(TM) anti-invasive biotherapy
- Category: DNA RNA and Cells
- Published on Friday, 30 May 2008 02:00
- Hits: 1612
BioAlliance Pharma presents new results on an innovative agent for treating invasive cancers at the 11th Annual Meeting of the American Society of Gene Therapy (ASGT) in Boston
PARIS, France | May 30, 2008 | BioAlliance Pharma SA (Euronext Paris: BIO; ISIN code: FR0010095596), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has presented new in vivo results for its new entity the AMEP™ plasmid at the 11th Annual Meeting of the American Society of Gene Therapy (ASGT) in Boston (May 28 to June 1, 2008).
AMEP(TM) (a plasmid coding for a peptide which binds to surface receptors on tumor cells) is a novel anti-invasive cancer therapy. In October 2007, BioAlliance announced highly promising results for AMEP(TM) administered directly within tumors. The new results presented at the ASGT meeting demonstrate the efficacy of AMEP(TM) when administered intramuscularly. AMEP™ prompted a 53% reduction in tumor growth (proof of concept established in a melanoma model).
"This new administration route demonstrates that AMEP(TM) has a global, systemic effect and broadens the perspectives for treatments, in particular for metastatic melanoma," stated Dominique Costantini, President of the Management Board and CEO at BioAlliance Pharma. "BioAlliance is gathering data to prepare the clinical trial application."
About BioAlliance Pharma
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc(R)) in France and already received European Marketing Authorizations in UK, Germany, Belgium, Denmark and Luxemburg. The compound has completed the pivotal Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad(R) in oral herpes (based on the same Lauriad(R) muco-adhesive technology as Loramyc(R), which enables targeted release at the disease site) and doxorubicin Transdrug(R) in primary liver cancer (based on the Transdrug(R) nanoparticle technology, designed specifically for intracellular targeting of resistant cells). The company is also developing a new therapeutic entities program focused on the oncology and infectious disease markets.
In 2007, the company has established strategic alliances for commercializing Loramyc(R) in Europe (with JV SpeBio) and in the USA with Par Pharmaceutical. In March 2008, BioAlliance Pharma signed a partnership agreement with Handok Pharmaceuticals for commercializing Loramyc(R) in Korea, Taiwan, Singapore and Malaysia. In May 2008, the company expanded its product portfolio via acquisition of the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD).
For more information, visit BioAlliance Pharma's website at www.bioalliancepharma.com.
SOURCE: BioAlliance Pharma SA